Compared with non-KRAS G12D, KRAS G12D has been reported to be associated with lower PD-L1 expression, a lower tumor mutation burden (TMB), increased immunosuppression, and enhanced resistance to immune checkpoint inhibitors (ICIs) [29, 30]. Here, KRAS is linked to neoplasm.